Clinical trial
A Phase III Study to Evaluate the Efficacy of Surovatamig Combined With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Previously Untreated Large B-cell Lymphoma (Soundtrack D3)
NCT07911553 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase III Study to Evaluate the Efficacy of Surovatamig Combined With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Previously Untreated Large B-cell Lymphoma (Soundtrack D3)
- Lead sponsor
- AstraZeneca
- Phase
- Phase 3
- Overall status
- Not yet recruiting
- Start date
- December 22, 2026
- Completion date
- September 1, 2032
- Enrollment
- 1,200 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
large b-cell lymphoma
Lead sponsor's other trials
AstraZeneca, most recent start first.
+3,493 more trials See the organization page
Similar trials
Same condition (Lymphoma, B-Cell) and phase, most recent start first.
+24 more trials See the condition page